Literature DB >> 17292332

Muc4 is required for activation of ErbB2 in signet ring carcinoma cell lines.

Atsushi Yokoyama1, Bin-Hai Shi, Takayuki Kawai, Hiroaki Konishi, Ryota Andoh, Hiroyuki Tachikawa, Sayoko Ihara, Yasuhisa Fukui.   

Abstract

Signet-ring cell carcinoma is one of the most malignant tumors, classified histologically as a poorly differentiated adenocarcinoma. The ErbB2/ErbB3 complex is often constitutively activated, which suggests that the ErbB2/ErbB3 signaling pathway may be important for malignancy of this tumor. However, the mechanism underlying this activation has not been understood. Here, we show that ErbB2 and Muc4 bind in signet ring carcinoma cells, which was not seen in highly differentiated adenocarcinoma cell lines. ErbB3 was suggested to be a substrate of ErbB2 because knockdown of ErbB2 resulted in less phosphorylation of ErbB3. Inhibition of expression of Muc4 at the cell surface by the treatment of the cells with benzyl-GalNac, an inhibitor of mucin secretion, blocked phosphorylation of ErbB3, suggesting that activity of ErbB2 depends on the expression of Muc4. These results supply the biochemical backgrounds in recent studies suggesting the contribution of Muc4 in the tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17292332     DOI: 10.1016/j.bbrc.2007.01.133

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.

Authors:  Albert C Chen; Ilenia Migliaccio; Mothaffar Rimawi; Sara Lopez-Tarruella; Chad J Creighton; Suleiman Massarweh; Catherine Huang; Yen-Chao Wang; Surinder K Batra; M Carolina Gutierrez; C Kent Osborne; Rachel Schiff
Journal:  Breast Cancer Res Treat       Date:  2012-05-29       Impact factor: 4.872

2.  Heregulin β-1 induces loss of cell-cell contact and enhances expression of MUC1 at the cell surface in HCC2998 and MKN45-1 cells.

Authors:  Rintaro Okoshi; Chung-Li Shu; Sayoko Ihara; Yasuhisa Fukui
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

3.  Signet ring cell variant of follicular thyroid carcinoma: Report of two cases with focus on morphological, expressional and genetic characteristics.

Authors:  Martin Hysek; Kenbugul Jatta; Adam Stenman; Eva Darai-Ramqvist; Jan Zedenius; Anders Höög; C Christofer Juhlin
Journal:  Diagn Pathol       Date:  2019-11-07       Impact factor: 2.644

Review 4.  Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology.

Authors:  Chiara Bazzichetto; Claudio Luchini; Fabiana Conciatori; Vanja Vaccaro; Ilaria Di Cello; Paola Mattiolo; Italia Falcone; Gianluigi Ferretti; Aldo Scarpa; Francesco Cognetti; Michele Milella
Journal:  Int J Mol Sci       Date:  2020-11-22       Impact factor: 5.923

5.  Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer.

Authors:  S Senapati; P Chaturvedi; P Sharma; G Venkatraman; J L Meza; W El-Rifai; H K Roy; S K Batra
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.